{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-022224","form_type":"8-K","ticker":null,"cik":"0001501756","company_name":"Adverum Biotechnologies, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.702644+00:00","generated_at":"2026-06-02T05:34:58.178493+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adverum Q1 net loss $24.8M; cash $193.3M; LUNA Phase 2 interim data to be presented in July","bullets":["Net loss of $24.8M ($1.50 per share) vs $29.1M in Q1 2023; R&D and G&A expenses decreased.","Cash, equivalents and short-term investments $193.3M as of March 31, 2024, up from $96.5M year-end; funds into late 2025.","LUNA Phase 2 interim analysis (26-week landmark) to be presented at ASRS July 17–20, 2024.","Preliminary LUNA data: 94% and 90% reduction in annualized anti-VEGF injections at 2E11 and 6E10 doses; 85% and 68% injection-free at 26 weeks.","Ixo-vec generally well tolerated; no serious adverse events, vasculitis, or vascular occlusion reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-022224","json":"https://secwatch.observer/filing/0001628280-24-022224.json","markdown":"https://secwatch.observer/filing/0001628280-24-022224.md","text":"https://secwatch.observer/filing/0001628280-24-022224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501756/000162828024022224/0001628280-24-022224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501756/000162828024022224/advm-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:34:58.178493+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a9c4576e06464feafa713d3dd788318ad79b0884","claim":"Adverum Biotechnologies, Inc. reported the quarter ended March 31, 2024 results: net income Net Loss was $24.8 million, or $1.50 per basic and diluted share, EPS $1.50 per basic and diluted share.","evidence_excerpt":"Net Loss was $24.8 million, or $1.50 per basic and diluted share, for the three months ended March 31, 2024, compared to $29.1 million, or $2.90 per basic and diluted share for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501756/000162828024022224/0001628280-24-022224-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"Net Loss was $24.8 million, or $1.50 per basic and diluted share"},{"label":"EPS","value":"$1.50 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}